Onxeo SA (ONXEO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Onxeo SA (ONXEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8117
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Onxeo SA (Onxeo) is a manufacturer of drugs that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company provides pipeline products such as livatag, belchop, beleodaq, amep, asidna and validive, among others. It offers drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer, among others. Onxeo’s livatag is a nanoparticle formulation of doxorubicin, which is developed for the treatment of primary liver cancer. The company provides preclinical and clinical development, regulatory affairs, and other services. It markets its products through its distribution network. Onxeo is headquartered in Paris, France.

Onxeo SA (ONXEO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onxeo SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Onxeo SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onxeo SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Onxeo Enters into Research Agreement with Royal College of Surgeons in Ireland 11
Onxeo Enters into Agreement with Centro de Investigacion Medica Aplicada 12
Onxeo Enters into Agreement with Croix-Rousse Hospital and Centre de Recherche en Cancerologie 13
Onxeo Enters into Agreement with Synovo 14
DARA BioSciences Enters into Commercialization Agreement with Onxeo 15
Licensing Agreements 16
SWK Holdings Receives Beleodaq Royalty Rights from Onxeo 16
Monopar Therapeutics Enters into Licensing Agreement with Onxeo 17
Pint Pharma Enters into Licensing Agreement with Onxeo for Beleodaq 18
Onxeo Enters into Licensing Agreement with Bruno Farmaceutici 19
Equity Offering 20
Onxeo to Raise USD6.3 Million in Equity Financing 20
Onxeo Raises USD16.7 Million in Private Placement of Shares 22
Onxeo Raises USD14 Million in Private Placement of Shares 23
Onxeo to Raise USD1 Million in Private Placement of Shares 24
Onxeo Raises USD51 Million in Rights Offering 25
Asset Transactions 27
Vectans Pharma to Acquire Sitavig and Loramyc from Onxeo 27
Acquisition 28
Onxeo Acquires DNA Therapeutics 28
Onxeo SA – Key Competitors 29
Onxeo SA – Key Employees 30
Onxeo SA – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 31
Recent Developments 33
Financial Announcements 33
Jul 27, 2018: Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook 33
May 16, 2018: Onxeo Provides Business Update and Reports First Quarter 2018 Financial Information 36
Mar 29, 2018: Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update 37
Oct 26, 2017: Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information 40
Jul 28, 2017: Onxeo Reports First-Half 2017 Results and Business Update 41
Apr 26, 2017: Onxeo: Q1 2017 financial information and business update 43
Mar 07, 2017: Onxeo: Full-year 2016 Results and Outlook for 2017 44
Corporate Communications 46
Mar 01, 2017: Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development 46
Mar 01, 2017: Onxeo announces two new executive appointments 47
Legal and Regulatory 48
Jan 23, 2018: Onxeo Announces Update On Litigation with SpeBio/SpePharm 48
Product News 49
Oct 02, 2017: Onxeo Introduces platON, a Proprietary Chemistry Platform of Decoy Oligonucleotides 49
04/24/2017: Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma 50
03/31/2017: Spectrum Pharmaceuticals Highlights Two Abstracts on BELEODAQ (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington 51
03/21/2017: Onxeo to Present Data on Key Orphan Oncology Asset Beleodaq at AACR Annual Meeting 52
Other Significant Developments 53
Mar 14, 2018: Onxeo Provides Financial Update 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Onxeo SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onxeo SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onxeo SA, Deals By Therapy Area, 2012 to YTD 2018 9
Onxeo SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onxeo Enters into Research Agreement with Royal College of Surgeons in Ireland 11
Onxeo Enters into Agreement with Centro de Investigacion Medica Aplicada 12
Onxeo Enters into Agreement with Croix-Rousse Hospital and Centre de Recherche en Cancerologie 13
Onxeo Enters into Agreement with Synovo 14
DARA BioSciences Enters into Commercialization Agreement with Onxeo 15
SWK Holdings Receives Beleodaq Royalty Rights from Onxeo 16
Monopar Therapeutics Enters into Licensing Agreement with Onxeo 17
Pint Pharma Enters into Licensing Agreement with Onxeo for Beleodaq 18
Onxeo Enters into Licensing Agreement with Bruno Farmaceutici 19
Onxeo to Raise USD6.3 Million in Equity Financing 20
Onxeo Raises USD16.7 Million in Private Placement of Shares 22
Onxeo Raises USD14 Million in Private Placement of Shares 23
Onxeo to Raise USD1 Million in Private Placement of Shares 24
Onxeo Raises USD51 Million in Rights Offering 25
Vectans Pharma to Acquire Sitavig and Loramyc from Onxeo 27
Onxeo Acquires DNA Therapeutics 28
Onxeo SA, Key Competitors 29
Onxeo SA, Key Employees 30
Onxeo SA, Subsidiaries 31
Onxeo SA, Joint Venture 31

List of Figures
Onxeo SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onxeo SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Onxeo SA (ONXEO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sandvik AB:企業の戦略・SWOT・財務分析
    Sandvik AB - Strategy, SWOT and Corporate Finance Report Summary Sandvik AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Medigus Ltd (MDGS):企業の財務・戦略的SWOT分析
    Summary Medigus Ltd (Medigus) is a medical device company that develops, produces and markets endoscopic surgical devices for minimally invasive medical procedures. The company flagship product, Medigus ultrasonic surgical endostapler (MUSE) system, a comprehensive endoscopic device for the treatmen …
  • Heerema International Group Services SA:企業の戦略的SWOT分析
    Heerema International Group Services SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Enercon Services Inc-エネルギー分野:企業M&A・提携分析
    Summary Enercon Services, Inc. (Enercon) is a diversified consulting company offering architectural engineering, environmental, technical and management services. Its offerings include licensing, operations, permitting, construction, decommissioning, and staff augmentation, cyber security and regula …
  • Square Inc:企業のM&A・事業提携・投資動向
    Square Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Square Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • BELECTRIC GmbH:電力:M&Aディール及び事業提携情報
    Summary Belectric GmbH (Belectric) is a renewable energy company that offers solar systems and solutions. The company manufactures, designs, and constructs photovoltaic rooftop installation systems for solar-projects and ground-mounted solar power plants. It manufactures BoS components, photovoltaic …
  • Ames Construction Inc:企業の戦略的SWOT分析
    Ames Construction Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Bausch & Lomb Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bausch & Lomb Inc (Bausch & Lomb), a subsidiary of Valeant Pharmaceuticals International Inc, is a vision-care company with focus on the protection, enhancement and restoration of eyesight. It offers over-the-counter supplements, eye care products, contact lenses, ophthalmic pharmaceuticals, …
  • Sage Therapeutics Inc (SAGE):製薬・医療:M&Aディール及び事業提携情報
    Summary Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics and medicines for central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The company ha …
  • Florida Keys Electric Cooperative Association, Inc.:企業の戦略的SWOT分析
    Florida Keys Electric Cooperative Association, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compe …
  • Taihan Electric Wire Co Ltd (001440):企業の財務・戦略的SWOT分析
    Taihan Electric Wire Co Ltd (001440) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Aksa Enerji Uretim AS (AKSEN):電力:M&Aディール及び事業提携情報
    Summary Aksa Enerji Uretim A.S. (Aksa Enerji), a subsidiary of Kazanci Holding A.S., is an independent power generation company. The company produces electricity through natural gas, fuel oil, hydro and wind power plants. Apart from power generation and sale, it also provides services such as projec …
  • Northwest Pipe Co (NWPX):企業の財務・戦略的SWOT分析
    Northwest Pipe Co (NWPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ITL Health Group (ITD):企業の財務・戦略的SWOT分析
    ITL Health Group (ITD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • TELUS Corporation:企業の戦略・SWOT・財務分析
    TELUS Corporation - Strategy, SWOT and Corporate Finance Report Summary TELUS Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • China Eastern Airlines Corporation Limited:企業の戦略・SWOT・財務分析
    China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Regis Healthcare Ltd:企業の戦略・SWOT・財務情報
    Regis Healthcare Ltd - Strategy, SWOT and Corporate Finance Report Summary Regis Healthcare Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • PRA Health Sciences Inc (PRAH):企業の財務・戦略的SWOT分析
    Summary PRA Health Sciences Inc (PRA) is a contract research organization (CRO) which provides clinical development services. The company offers services which include phase I-IV study management, bioanalytical services, biometrics, clinical pharmacology, strategic solutions, post-marketing research …
  • Rafako SA (RFK):企業の財務・戦略的SWOT分析
    Rafako SA (RFK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Targa Resources Corp (TRGP):企業の財務・戦略的SWOT分析
    Targa Resources Corp (TRGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆